SCHEMBL1825264

SCHEMBL1825264

CC(C)OC(=O)C(CNC(=O)OC(C)(C)C)c1ccc(OS(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.41
EGFR P00533 1/20 0.41
SYK P43405 1/20 0.40
ADAMTS4 O75173 1/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
P2RX7 Q99572 8/20 0.39
GPR88 Q9GZN0 1/20 0.38
ALDH1A1 P00352 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ENPP3 O14638 2/20 0.38
ENPP1 P22413 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
BCL2 P10415 1/20 0.37
ENPP2 Q13822 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827842 0.92 EGFR (0.43) MMP13EGFRSYKADAMTS4CTSS
SCHEMBL1826219 0.91 EGFR (0.42) MMP13EGFRP2RX7ALDH1A1ENPP3
SCHEMBL1824701 0.91 EGFR (0.43) MMP13EGFRSYKADAMTS4CTSS
SCHEMBL1825441 0.89 MMP13 (0.39) MMP13EGFRSYKCTSSCTSK
SCHEMBL1827339 0.89 SYK (0.43) MMP13EGFRSYKADAMTS4CTSS
SCHEMBL1823128 0.87 SYK (0.51) MMP13EGFRSYKP2RX7CA12
SCHEMBL1824426 0.86 SYK (0.39) MMP13EGFRSYKCTSSCTSK
SCHEMBL1822702 0.86 ADAMTS4 (0.43) MMP13ADAMTS4ALDH1A1SMN1; SMN2ENPP3
SCHEMBL1825193 0.86 CA1 (0.45) MMP13CTSSCTSKP2RX7CA1
SCHEMBL1825581 0.84 EGFR (0.40) MMP13EGFRSYKADAMTS4CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 MMP13 4589/4885EGFR 1025/4885SYK 1520/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 MMP13 4114/4885EGFR 1471/4885SYK 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.